Table 3 Postoperative adjuvant chemotherapy related adverse reactions
AE | ALL (n = 64) | GX groups (n = 22) | GP groups (n = 18) | X groups (n = 24) | ||||
|---|---|---|---|---|---|---|---|---|
Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | |
Nausea | 44(68.8%) | 0 | 15(68.2%) | 0 | 14(77.8%) | 0 | 15(62.5%) | 0 |
Diarrhea | 31(48.4%) | 3(4.7%) | 10(45.5%) | 0 | 8(44.4%) | 0 | 13(54.2%) | 3(12.5%) |
Rash | 28(43.8%) | 0 | 10(45.5%) | 0 | 7(38.9%) | 0 | 11(45.8%) | 0 |
Hand-foot syndrome | 25(39.1%) | 0 | 11(50.0%) | 0 | 5(27.8%) | 0 | 9(37.5%) | 0 |
Fatigue | 30(46.9%) | 5(7.8%) | 11(50.0%) | 0 | 7(38.9%) | 3(16.7%) | 12(50.0%) | 2(8.3%) |
Leucopenia | 16(25.0%) | 7(10.9%) | 9(40.9%) | 4(18.2%) | 5(27.8%) | 1(5.6%) | 2(8.3%) | 2(8.3%) |
Anemia | 30(46.9%) | 4(6.3%) | 11(50.0%) | 4(18.2%) | 11(61.1%) | 0 | 8(33.3%) | 0 |
Thrombocytopenia | 28(43.8%) | 2(3.1%) | 14(63.6%) | 1(4.5%) | 7(38.9%) | 1(5.6%) | 7(29.2%) | 0 |
ALT elevation | 35(54.7%) | 0 | 15(68.2%) | 0 | 8(44.4%) | 0 | 12(50.0%) | 0 |
AST elevation | 48(75.0%) | 0 | 16(72.7%) | 0 | 11(77.8%) | 0 | 18(75.0%) | 0 |
TBIL elevation | 32(50.0%) | 0 | 16(72.7%) | 0 | 7(38.9%) | 0 | 9(37.5%) | 0 |
Proteinuria | 31(48.4%) | 2(3.1%) | 9(40.9%) | 2(9.1%) | 8(44.4%) | 0 | 14(58.3%) | 0 |
Hematuresis | 21(32.8%) | 2(3.1%) | 10(45.5%) | 2(9.1%) | 6(33.3%) | 0 | 5(20.8%) | 0 |
Creatinine elevation | 30(46.9%) | 0 | 12(54.5%) | 0 | 6(33.3%) | 0 | 12(50.0%) | 0 |